PFM Health Sciences’s Xenon Pharmaceuticals XENE Stock Holding History

PFM Health Sciences’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-92,236	Closed	-$3.09M	–	78
2025 Q1	$3.09M	Sell	92,236 -24,762	-21%	-$940K	0.22%	48
2024 Q4	$4.59M	Sell	116,998 -62,880	-35%	-$2.6M	0.28%	56
2024 Q3	$7.08M	Buy	179,878 +29,324	+19%	+$1.18M	0.4%	46
2024 Q2	$5.87M	Hold	150,554	–	–	0.29%	55
2024 Q1	$6.48M	Sell	150,554 -42,302	-22%	-$1.95M	0.3%	64
2023 Q4	$8.88M	Buy	192,856 +114,269	+145%	+$4.04M	0.53%	46
2023 Q3	$2.68M	Sell	78,587 -21,560	-22%	-$806K	0.13%	67
2023 Q2	$3.86M	Hold	100,147	–	–	0.15%	71
2023 Q1	$3.58M	Buy	100,147 +82,659	+473%	+$3.05M	0.16%	66
2022 Q4	$690K	Buy	+17,488	New	+$637K	0.02%	83

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PFM Health Sciences's XENE Position: Q2 2025 in Review

PFM Health Sciences sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 92,236 shares — an estimated $3.09M sold.

PFM Health Sciences first reported a position in XENE in Q4 2022 and held it in 10 quarters. The position peaked at $8.88M in Q4 2023. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

PFM Health Sciences reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
PFM Health Sciences sold 92,236 Xenon Pharmaceuticals shares in Q2 2025, an estimated $3.09M.
PFM Health Sciences first reported a position in Xenon Pharmaceuticals in Q4 2022 and held it in 10 quarters.
PFM Health Sciences's Xenon Pharmaceuticals position peaked at $8.88M in Q4 2023.
206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on PFM Health Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.